ABOUT US
ONTRACK Biomedical AG is committed to improving the quality of life of patients by developing non-invasive in-vitro diagnostic tests for the diagnosis and monitoring of cancer. We are a MedTech spin-off of the University of Zurich and University Hospital Zurich, incorporated in January 2023. The academic research underpinning our prostate cancer urine test began in 2018 at the University of Zurich with ONtrack Diagnostics, supported by multiple competitive grants
FIRST PIPELINE PRODUCT
Our first pipeline product is a urine test designed as an aid in the decision for prostate biopsy in men with clinical suspicion of prostate cancer. It is intended to identify individuals who do not have prostate cancer, reducing unnecessary biopsies, and to support the identification of clinically significant prostate cancer. It is also designed to support active surveillance of indolent prostate cancer, replacing repeat biopsies with a simple urine test. ONtrack's urine test is currently under development and is not yet available on the market.
ACADEMIC SUPPORT
FOUNDERS
Our five Founders comprise highly experienced scientists, clinicians and entrepreneurs, whose joined skills generate ONTRACK Biomedical’s core asset: an innovative R&D platform and extensive MedTech business expertise.
